Home › Trials › NCT06693531

Registry of patients with eosinophilic esophagitis treated with DUPIXENT

A U.S. Registry of Eosinophilic Esophagitis Patients Treated With DUPIXENT® As Standard of Care

Observational Regeneron Pharmaceuticals · NCT06693531

This study looks at how well DUPIXENT helps people with eosinophilic esophagitis feel and live better after starting the treatment.

Quick facts

Study typeObservational
Enrollment350 (estimated)
Ages1 Year and up
SexAll
SponsorRegeneron Pharmaceuticals Industry-sponsored
Drugs / interventionsdupilumab
Locations54 sites (Phoenix, Arizona and 53 other locations)
Trial IDNCT06693531 on ClinicalTrials.gov

What this trial studies

This observational research focuses on patients with eosinophilic esophagitis (EoE) who have recently started treatment with DUPIXENT® (dupilumab). The study aims to gather data on the usage of DUPIXENT in standard care for EoE, assessing various aspects such as symptoms, quality of life, and the impact of EoE on daily activities. Patient questionnaires will be utilized to measure these factors over the course of the study, providing insights into the effectiveness of the treatment in real-world settings.

Who should consider this trial

Good fit: Ideal candidates include adolescents and adults initiating treatment with DUPIXENT® for eosinophilic esophagitis.

Not a fit: Patients with contraindications to DUPIXENT® or those who have received the treatment within the last six months may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could enhance understanding of eosinophilic esophagitis and inform future treatment decisions and clinical trial designs.

How similar studies have performed: While this study is observational, similar approaches in understanding treatment impacts in chronic conditions have shown promise in enhancing patient care.

Eligibility criteria

Show full inclusion / exclusion criteria 
Key Inclusion Criteria:

1. Initiating treatment with DUPIXENT® for EoE according to the USPI
2. Participants aged ≥12 years and caregivers or legal guardians of participants aged \<12 years must be able to understand and complete registry-related questionnaires

Key Exclusion Criteria:

1. Patients who have a contraindication to DUPIXENT® according to the USPI
2. Treatment with DUPIXENT® within the 6 months prior to the screening assessment
3. Participation in an ongoing interventional study on or within 6 months of the baseline assessment. Once enrolled in registry, participation is allowed in other ongoing studies (at the discretion of the registry investigator)

NOTE: Other protocol defined inclusion/exclusion criteria apply

Where this trial is running

Phoenix, Arizona and 53 other locations

+4 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Eosinophilic Esophagitis
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.